BRD4 and Hepatic fibrosis: Importantly, pharmacologic inhibition of YAP or BRD4 with small molecules that disrupt their respective interactions with cofactors has produced promising antifibrotic responses in murine liver fibrosis models (Ding et al., 2015; Mannaerts et al., 2015) and thus, represents an attractive therapeutic approach to treat liver fibrosis in patients.